MARKET

RTRX

RTRX

Retrophin
NASDAQ

Real-time Quotes | Nasdaq Last Sale

18.06
-0.21
-1.15%
Opening 11:19 08/12 EDT
OPEN
18.36
PREV CLOSE
18.27
HIGH
18.60
LOW
18.00
VOLUME
112.70K
TURNOVER
--
52 WEEK HIGH
21.92
52 WEEK LOW
8.98
MARKET CAP
919.36M
P/E (TTM)
-7.0807
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 8 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average RTRX stock price target is 29.14 with a high estimate of 38.00 and a low estimate of 21.00.

EPS

RTRX News

More
Retrophin to Present at Upcoming Investor Conferences
SAN DIEGO, Aug. 03, 2020 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced that Company management will participate in the following upcoming virtual investor conferences in August: William Blair Biotech Focus Conference 2020 Date: Thursday,
GlobeNewswire · 08/03 20:30
Retrophin (RTRX) Reports Q2 Loss, Misses Revenue Estimates
Retrophin (RTRX) delivered earnings and revenue surprises of 0.00% and -0.14%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 07/30 22:40
Retrophin Q2 EPS $(0.22) Beats $(0.55) Estimate, Sales $48.40M Beat $47.08M Estimate
Retrophin (NASDAQ:RTRX) reported quarterly losses of $(0.22) per share which beat the analyst consensus estimate of $(0.55) by 60 percent. This is a 62.07 percent increase over losses of $(0.58) per share from the same
Benzinga · 07/30 20:13
Retrophin Reports Second Quarter 2020 Financial Results
Enrollment ahead of schedule in Phase 3 PROTECT Study of sparsentan in IgAN; topline proteinuria data from both pivotal studies in FSGS and IgAN now anticipated in 2021 Net product sales increased eight percent to $48 million in the second quarter Cash & equi
GlobeNewswire · 07/30 20:01
The Daily Biotech Pulse: Bristol-Myers, Bluebird Bio Resubmit Multiple Myeloma Drug BLA, FSD To Close Medicinal Cannabis Business, Hologic's Blowout Quarter
Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 29)
Benzinga · 07/30 12:09
Retrophin EPS beats by $0.14, beats on revenue
Seeking Alpha · 07/30 04:00
The Week Ahead In Biotech: Spotlight On GW Pharma, Ultragenyx FDA Decisions, Pfizer Earnings
Biotech stocks moved lower in the week ended July 26, as the broader market weakness and sector-specific developments pressured stocks.
Benzinga · 07/26 13:55
Retrophin (RTRX) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
Retrophin (RTRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks · 07/23 16:33

Industry

Biotechnology & Medical Research
+0.23%
Pharmaceuticals & Medical Research
+1.47%

Hot Stocks

Symbol
Price
%Change

About RTRX

Retrophin, Inc. is a biopharmaceutical company. The Company is focused on the development, acquisition and commercialization of therapies for the treatment of serious, catastrophic or rare diseases. The Company sells three products, including Chenodal (chenodeoxycholic acid), Cholbam (cholic acid) and Thiola (tiopronin). Its Chenodal is approved in the United States for the treatment of patients suffering from gallstones in whom surgery poses an unacceptable health risk due to disease or advanced age. Chenodal has also been care for cerebrotendinous xanthomatosis (CTX) patients. Its Cholbam is approved in the United States for the treatment of bile acid synthesis disorders due to single enzyme defects and is further indicated for adjunctive treatment of patients with peroxisomal disorders. Its Thiola is approved in the United States for the prevention of cystine (kidney) stone formation in patients with severe homozygous cystinuria.
More

Webull offers kinds of Retrophin Inc stock information, including NASDAQ:RTRX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, RTRX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading RTRX stock methods without spending real money on the virtual paper trading platform.